Benitec, Genta and Invitrogen

Dec 12, 2003

Premium

Benitec Closes AU$11 Million Private Placement

Benitec closed this week an AU$11 million ($8.1 million) placement of its common stock with institutional investors in Europe and Australia, Benitec CEO John McKinley told RNAi News this week.

McKinley noted that the company remains on track to moving its stock from the Australian Stock Exchange to a US exchange next year, and is in the process of incorporating in Delaware.

Genta Completes US Regulatory Filing for Antisense Cancer Drug

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

12

Featured Webinar

GenomeWeb/ABRF 2017 Webinar Series: Next-Generation CRISPR: New Tools for Efficient Genome Engineering

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.

Main menu